Practical Fragments

Just over two years ago we highlighted a new clinical candidate targeting WRN, a covalent inhibitor then called VVD-133214. An open-access ...

It’s been a couple years since Practical Fragments last updated our “fragments in the clinic” list . Before doing so it makes sense to high...

Last week’s CHI Drug Discovery Chemistry (DDC) meeting was held as usual in San Diego. More than 850 people attended, 96% in person, with 7...

As the title states, this is the 1000 th post at Practical Fragments . This blog was conceived in 2008 over drinks at the Third Annual CHI ...

At the end of 2023 I mentioned that a paper by Dean Brown listed berotralstat as a fragment-derived drug. Readers will notice this molecule...

Back in 2016 we highlighted a paper describing chemoproteomic screening of covalent fragments. That technology formed the basis of Vividion...

It has been more than a year since our last list of fragment-derived clinical compounds. Since then capivasertib has been approved, bringi...

On Thursday last week the FDA approved capivasertib for certain breast cancer patients. This marks the seventh fragment-derived drug to be...

In the US we're about to celebrate Thanksgiving . One of the things I'm thankful for is the discovery of new medicines, so this seem...

Of the 50+ fragment-derived drugs that have entered the clinic , only two (both from Sosei Heptares) target transmembrane proteins, reflecti...

Practical Fragments ’ first list of fragment-derived clinical compounds, published in 2009, listed just 17 molecules. The current count is...

Bromodomains, which recognize acetylated lysine residues, are popular cancer targets due to their role in gene regulation. A plethora of po...

CHI’s Drug Discovery Chemistry (DDC) meeting took place last week in San Diego. I think this was the largest yet, with >825 attendees, a...